Last reviewed 2026-04-21 · How we verify

Abilify MyCite®

Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence.

Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).

At a glance

Mechanism of action

Aripiprazole works by acting as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, helping to restore balance in neurotransmitter activity in the brain. The MyCite formulation includes an ingestible sensor that detects when the medication is ingested and transmits this information to a wearable patch and mobile app, enabling real-time monitoring of medication adherence. This digital health component is designed to improve treatment outcomes by providing patients, caregivers, and healthcare providers with objective adherence data.

Approved indications

• Schizophrenia
• Bipolar I disorder (acute manic or mixed episodes)
• Major depressive disorder (adjunctive treatment)

Common side effects

• Akathisia
• Tremor
• Headache
• Nausea
• Insomnia
• Weight gain
• Sedation

Key clinical trials

• A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion (NA)
• Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (PHASE4)
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.